| abstract |
A therapeutic agent for irritable bowel syndrome which contains as an active ingredient a compound having adenosine uptake inhibitory activity; and a therapeutic agent for irritable bowel syndrome which contains as an active ingredient either a tricyclic compound represented by the formula (I) [wherein L represents -NHC(=O)-, etc.; R1 represents hydrogen, halogeno, etc.; X1-X2-X3 represents S-CR7=CR8 (wherein R7 and R8 are the same or different and each represents hydrogen, halogeno, (un)substituted lower alkyl, etc.), etc.; Y represents -CH2SO2-, -SO2CH2-, etc.; and R2 represents (un)substituted lower alkyl, (un)substituted lower alkoxy, (un)substituted aryl, etc.] or a pharmacologically acceptable salt of the compound. |